Mineralys Therapeutics (MLYS) Free Cash Flow (2022 - 2026)

Mineralys Therapeutics has reported Free Cash Flow for 5 years, with the latest figure at -$39.5 million in Q1 2026.

• Quarterly Free Cash Flow rose 13.23% year-over-year to -$39.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$136.4 million (up 29.21% YoY) and the FY2025 annual result came in at -$142.4 million, up 14.41% from the prior year.
• Free Cash Flow fell to -$39.5 million in Q1 2026 per MLYS's latest filing, from -$37.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$5.5 million in Q2 2022 and troughed at -$66.8 million in Q4 2024.
• A 5-year average of -$27.0 million and a median of -$28.8 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 272.76% in 2023, then surged 43.25% in 2025.
• Over 5 years, Free Cash Flow stood at -$10.2 million in 2022, then slumped by 184.52% to -$29.0 million in 2023, then slumped by 130.64% to -$66.8 million in 2024, then soared by 43.25% to -$37.9 million in 2025, then slipped by 4.06% to -$39.5 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$39.5 million, -$37.9 million, and -$28.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.